再次冠状动脉搭桥中多支动脉桥的获益:动脉类型与性别的影响
该研究纳入1980至2020年间6559例再次冠状动脉搭桥患者,经倾向性评分匹配后比较多支动脉桥与单支动脉桥(联合或不联合静脉桥)各2005对。
要点
- 再次冠脉搭桥中多支动脉桥院内死亡率低于单支动脉桥(1.7% vs 2.8%)。
- 多支动脉桥长期生存更优,但获益仅见于双支胸廓内动脉的男性患者。
- 两组主要术后并发症发生率相似。
核心结论
- 多支动脉桥用于再次冠状动脉搭桥可降低院内死亡率,主要并发症与单支动脉桥相似,并改善长期生存,但获益主要限于使用双支胸廓内动脉的男性患者。
研究设计与样本
- 回顾性队列研究,纳入1980年1月至2020年7月共6559例成人再次冠状动脉搭桥患者(共6693次手术)。
- 多支动脉桥组与单支动脉桥组(联合或不联合静脉桥)经倾向性评分匹配,得到2005对匹配患者。
- 中位随访10年,25%患者随访超过17年。
- 采用多变量多相风险模型和非参数随机生存森林模型分析生存。
主要发现
- 匹配后多支动脉桥组与单支动脉桥组术后并发症:再次手术50例(2.5%)vs 65例(3.2%),肾衰竭73例(3.6%)vs 55例(2.7%),卒中44例(2.2%)vs 38例(1.9%),深部胸骨感染36例(1.8%)vs 25例(1.2%)。
- 总体生存率多支动脉桥组 vs 单支动脉桥组:1年95% vs 94%,3年92% vs 88%,5年87% vs 82%,15年49% vs 42%,20年31% vs 25%。
临床怎么用
- 再次冠状动脉搭桥时可考虑多支动脉桥以降低院内死亡率并改善长期生存。
- 多支动脉桥的生存获益主要见于使用双支胸廓内动脉的男性患者,选择患者时应考虑性别和动脉桥类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether multiarterial grafting provides an incremental benefit above single arterial grafting in isolated redo coronary artery bypass grafting (CABG). METHODS: From January 1980 to July 2020, 6559 adults underwent a total of 6693 isolated CABG reoperations. Patients undergoing multiarterial grafting were propensity score-matched with those undergoing single arterial grafting with or without additional vein grafts, yielding 2005 well-matched pairs. Endpoints were in-hospital postoperative complications, hospital mortality, and long-term mortality. The median follow-up was 10 years, with 25% of patients followed for >17 years. Multivariable multiphase hazard models and nonparametric random survival forest models for survival were used to identify patients for whom multiarterial grafting was most beneficial. RESULTS: Among propensity score-matched patients, postoperative complications in multiarterial versus single arterial grafting included any reoperation (50 [2.5%] vs 65 [3.2%]); renal failure (73 [3.6%] vs 55 [2.7%]), stroke (44 [2.2%] vs 38 [1.9%]), and deep sternal infection (36 [1.8%] vs 25 [1.2%]). In-hospital mortality was 1.7% (n = 35) in multiarterial grafting versus 2.8% (n = 56) in single arterial grafting (P = .03). Comparing multiarterial to single arterial grafting, overall survival was 95% versus 94% at 1 year, 92% versus 88% at 3 years, 87% versus 82% at 5 years, 49% versus 42% at 15 years, and 31% versus 25% at 20 years. Better survival after multiarterial grafting was confined to males with 2 patent internal thoracic artery grafts (P < .0001). CONCLUSIONS: Redo CABG with multiarterial grafting can be performed with lower in-hospital mortality and similar major morbidity to single arterial grafting. It is associated with better long-term survival, particularly in males when 2 internal thoracic artery grafts are used.
引用
- Iacona GM, Bakhos JJ, Houghtaling PL, et al. Multiarterial grafting in redo coronary artery bypass grafting: Type of arterial conduit and patient sex determine benefit. J Thorac Cardiovasc Surg. 2024. PMID: 39426712. doi:10.1016/j.jtcvs.2024.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。